RxDoctor Payments Data

Jeffrey Kaplan, MD

Ophthalmology · Bridgeport, CTNPI 1952395568

Payments from drug & device makers

$2,309in general payments, 2019–2025

Across 83 payments — averaging $27.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$542
  • Bausch & Lomb Americas Inc.$466
  • AbbVie$465
  • Sun Pharmaceutical Industries Inc.$152
  • Sight Sciences, Inc.$130
  • Aerie Pharmaceuticals, Inc.$67
  • plus $486 from 14 others

What the payments were for

  • Travel & lodging$121%
  • Food & beverage$2,27799%
  • Gifts$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,309 in reported general payments places this provider in the 70th percentile of 279 ophthalmology providers in Connecticut.

See all ophthalmology providers in Connecticut

Medicare billing

Part B allowed, 2024
$248,383
Medicare patients
846
Services billed
1,867

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine74$106,520
LumiganBimatoprost98$42,214
Cyclosporine23$8,471
Brimonidine Tartrate30$4,252
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol40$3,770
Brinzolamide17$3,210
Latanoprost328$3,023
Timolol Maleate168$1,853
Loteprednol Etabonate11$1,370
Prednisolone Acetate37$1,037
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat45$907
ErythromycinErythromycin Base83$852
Dorzolamide Hcl20$400
Tobramycin-DexamethasoneTobramycin/Dexamethasone13$330
ValacyclovirValacyclovir Hcl17$327

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$465$148,734172 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$12$1,37011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 279 ophthalmology providers in Connecticut.

Other ophthalmology in Bridgeport

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →